The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant p53 helps tumor tissue evade the killing effect of the immune system by inhibiting the anti-tumor immune response.223,247,248”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [248]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · cited 3×
“Myriad studies have shown that p53 plays an important role in tumor suppression via promoting cell cycle arrest and apoptosis [14].”
Background
Research works printed but not linked: 37
- 10.1002/ijc.25516 · DOI · Paper page
- Addeo R., Caraglia M. and Iuliano G.: Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. Expert Opin Biol Ther 2016; 16: 1075. · DOI
- Li X., Shao C., Shi Y. and Han W.: Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol 2018; 11: 31. · DOI · Paper page
- 10.1158/1078-0432.CCR-16-0066 · DOI · Paper page
- 10.1056/NEJMoa1406498 · DOI · Paper page
- 10.1126/science.aaa1348 · DOI · Paper page
- 10.1158/1078-0432.CCR-13-3271 · DOI · Paper page
- 10.1056/NEJMoa1500596 · DOI · Paper page
- 10.18632/oncotarget.13483 · DOI
- Cancer Genome Atlas N : Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517: 576. · DOI · Paper page
- Zitvogel L. and Kroemer G.: CANCER. A p53-regulated immune checkpoint relevant to cancer. Science 2015; 349: 476. · DOI
- 10.1158/0008-5472.CAN-11-4134 · DOI · Paper page
- 10.1016/j.immuni.2017.11.016 · DOI · Paper page
- 10.1007/s00262-017-2005-z · DOI · Paper page
- 10.1002/ijc.29649 · DOI · Paper page
- 10.1097/CCO.0000000000000234 · DOI
- 10.1038/264145a0 · doi:10.1038/264145a0
- Wang B., Niu D., Lai L. and Ren E.C.: p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun 2013; 4: 2359. · DOI
- Davoli T., Uno H., Wooten E.C. and Elledge S.J.: Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017; 355. · DOI · Paper page
- Fritsch E.F., Hacohen N. and Wu C.J.: Personal neoantigen cancer vaccines: the momentum builds. Oncoimmunology 2014; 3: e29311. · DOI
- 10.1111/ejh.12427 · DOI · Paper page
- 10.1038/35021086 · DOI · Paper page
- Vrba L., Junk D.J., Novak P. and Futscher B.W.: p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics 2008; 9: 486. · DOI
- 10.1034/j.1600-065X.2003.00015.x · DOI · Paper page
- Ben Safta T., Ziani L., Favre L., Lamendour L., Gros G. et al: Granzyme B-activated p53 interacts with Bcl-2 to promote cytotoxic lymphocyte-mediated apoptosis. J Immunol 2015; 194: 418. · DOI
- 10.1074/jbc.275.10.7337 · DOI · Paper page
- 10.1016/j.tranon.2016.10.005 · doi:10.1016/j.tranon.2016.10.005
- 10.1186/s40425-016-0165-6 · DOI · Paper page
- 10.1038/bjc.2011.189 · DOI · Paper page
- 10.1016/j.tranon.2018.07.012 · DOI · Paper page
- 10.1080/14712598.2017.1309387 · DOI
- 10.1016/j.immuni.2016.10.021 · DOI · Paper page
- 10.1038/nature08460 · DOI · Paper page
- Benjamini Y. and Hochberg Y.: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B 1995; 57: 289. · DOI · Paper page
- 10.1093/nar/gkw1092 · DOI · Paper page
- 10.1038/nbt.2203 · DOI · Paper page
- Kim S.: Ppcor: an R package for a fast calculation to semi-partial correlation coefficients. Commun Stat Appl Methods 2015; 22: 665.
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Mutant p53 suppresses innate immune signaling to promote tumorigenesis
Ghosh, M., Saha, S., Bettke, J., Nagar, R., Parrales, A., Iwakuma, T., van der Velden, A. W. M., & Martinez, L. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.003 · Cited by 348
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02903 · Cited by 208
Metadata
- Authors
- Lyu, H., Li, M., Jiang, Z., Liu, Z., & Wang, X.
- Affiliations
- Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2019-01
- Volume
- 17
- Pages
- 1020-1030
- ISSN
- 2001-0370
- Cited by
- 111
- References
- 18
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 203 d)
- Funders
- China Pharmaceutical University
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer. https://app.cochat.ai/papers/10.1016/j.csbj.2019.07.009
- The paper
- Lyu, H., Li, M., Jiang, Z., Liu, Z., & Wang, X. (2019). Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer. Computational and Structural Biotechnology Journal. https://doi.org/10.1016/j.csbj.2019.07.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
